Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Bayer Research Alliance Bears First Fruit

NEW YORK, Jan. 31 - The $1.4 billion obesity and diabetes research partnership launched by Bayer and CuraGen has begun to bear fruit, the companies said on Wednesday.

 

The two have chosen 31 small molecule targets in obesity and diabetes and have finished screening against four of those targets. The CuraGen targets are designated as "high priority" for screening at Bayer, the companies said in a statement.

 

The two companies struck their massive deal in early 2001. CuraGen agreed to provide 80 drug targets for obesity and diabetes in the course of five years. The two jointly agreed to bring 12 drugs to clinical development, sharing both late-stage preclinical and clinical development costs and profits for any resulting drugs.

 

In the arrangement, announced roughly one year ago, CuraGen is supplying its pharmacogenomic, bioinformatics, and functional genomics knowledge, and Bayer is handling high-throughput screening, combinatorial chemistry, medicinal chemistry, and pharmacology.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.